25 XP   0   0   10

Kuros Biosciences AG
Buy, Hold or Sell?

Let's analyse Kuros together

PenkeI guess you are interested in Kuros Biosciences AG. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Kuros Biosciences AG. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Kuros Biosciences AG

I send you an email if I find something interesting about Kuros Biosciences AG.

Quick analysis of Kuros (30 sec.)










What can you expect buying and holding a share of Kuros? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.54
Expected worth in 1 year
$1.21
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
$-0.33
Return On Investment
-3.7%

For what price can you sell your share?

Current Price per Share
$9.00
Expected price per share
$6.3 - $9.05
How sure are you?
50%

1. Valuation of Kuros (5 min.)




Live pricePrice per Share (EOD)

$9.00

Intrinsic Value Per Share

$-3.78 - $-4.40

Total Value Per Share

$-2.25 - $-2.86

2. Growth of Kuros (5 min.)




Is Kuros growing?

Current yearPrevious yearGrowGrow %
How rich?$56.7m$71.9m-$11.6m-19.3%

How much money is Kuros making?

Current yearPrevious yearGrowGrow %
Making money-$5.6m-$5.9m$356k6.3%
Net Profit Margin-40.6%-80.9%--

How much money comes from the company's main activities?

3. Financial Health of Kuros (5 min.)




4. Comparing to competitors in the Medical Devices industry (5 min.)




  Industry Rankings (Medical Devices)  

What can you expect buying and holding a share of Kuros? (5 min.)

Welcome investor! Kuros's management wants to use your money to grow the business. In return you get a share of Kuros.

What can you expect buying and holding a share of Kuros?

First you should know what it really means to hold a share of Kuros. And how you can make/lose money.

Speculation

The Price per Share of Kuros is $9. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Kuros.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Kuros, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.54. Based on the TTM, the Book Value Change Per Share is $-0.08 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.06 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Kuros.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.26-2.9%-0.15-1.7%-0.11-1.2%-0.10-1.1%-0.10-1.1%
Usd Book Value Change Per Share0.010.1%-0.08-0.9%-0.06-0.6%-0.03-0.3%0.050.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.010.1%-0.08-0.9%-0.06-0.6%-0.03-0.3%0.050.5%
Usd Price Per Share3.85-2.44-2.08-2.05-1.37-
Price to Earnings Ratio-3.74--4.34--6.58--47.49--31.66-
Price-to-Total Gains Ratio465.33-17,535.41--17.54-6,394.08-6,394.08-
Price to Book Ratio2.50-1.52-1.06-1.06-0.71-
Price-to-Total Gains Ratio465.33-17,535.41--17.54-6,394.08-6,394.08-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share9
Number of shares111
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.08-0.03
Usd Total Gains Per Share-0.08-0.03
Gains per Quarter (111 shares)-9.14-2.98
Gains per Year (111 shares)-36.56-11.90
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-37-470-12-22
20-73-840-24-34
30-110-1210-36-46
40-146-1580-48-58
50-183-1950-60-70
60-219-2320-71-82
70-256-2690-83-94
80-293-3060-95-106
90-329-3430-107-118
100-366-3800-119-130

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.030.00.00.0%2.048.00.04.0%
Book Value Change Per Share2.02.00.050.0%3.05.04.025.0%5.07.08.025.0%9.09.012.030.0%14.021.015.028.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.030.00.0%0.00.050.00.0%
Total Gains per Share2.02.00.050.0%3.05.04.025.0%5.07.08.025.0%9.09.012.030.0%14.021.015.028.0%

Fundamentals of Kuros

About Kuros Biosciences AG

Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through three segments: Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold use to fill bony voids for a predictable fusion; MagnetOs Easypack Putty, a ready-to-use mold to be implanted in any intervertebral disc space or posterolateral spine level; and Magnetos Flex Matrix, an open matrix bone graft. Its Fibrin-PTH pipeline products comprise KUR-111 and KUR-113 that are in Phase 2b clinical trials for trauma indications; KUR-113 that is in Phase 2a clinical trial for spinal indications. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.

Fundamental data was last updated by Penke on 2024-05-15 22:27:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Kuros Biosciences AG.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Kuros earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Kuros to the Medical Devices industry mean.
  • A Net Profit Margin of -41.9% means that $-0.42 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Kuros Biosciences AG:

  • The MRQ is -41.9%. The company is making a huge loss. -2
  • The TTM is -40.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-41.9%TTM-40.6%-1.3%
TTM-40.6%YOY-80.9%+40.3%
TTM-40.6%5Y-81.7%+41.2%
5Y-81.7%10Y-7,576.6%+7,494.9%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-41.9%-10.8%-31.1%
TTM-40.6%-17.8%-22.8%
YOY-80.9%-13.3%-67.6%
5Y-81.7%-19.6%-62.1%
10Y-7,576.6%-24.5%-7,552.1%
1.1.2. Return on Assets

Shows how efficient Kuros is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Kuros to the Medical Devices industry mean.
  • -12.5% Return on Assets means that Kuros generated $-0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Kuros Biosciences AG:

  • The MRQ is -12.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -7.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.5%TTM-7.4%-5.1%
TTM-7.4%YOY-7.1%-0.3%
TTM-7.4%5Y-4.4%-3.0%
5Y-4.4%10Y-4.7%+0.2%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.5%-3.6%-8.9%
TTM-7.4%-4.2%-3.2%
YOY-7.1%-3.8%-3.3%
5Y-4.4%-3.7%-0.7%
10Y-4.7%-4.3%-0.4%
1.1.3. Return on Equity

Shows how efficient Kuros is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Kuros to the Medical Devices industry mean.
  • -16.7% Return on Equity means Kuros generated $-0.17 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Kuros Biosciences AG:

  • The MRQ is -16.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -9.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-16.7%TTM-9.5%-7.2%
TTM-9.5%YOY-8.5%-1.0%
TTM-9.5%5Y-5.3%-4.2%
5Y-5.3%10Y-5.5%+0.2%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-16.7%-3.7%-13.0%
TTM-9.5%-4.7%-4.8%
YOY-8.5%-4.8%-3.7%
5Y-5.3%-5.6%+0.3%
10Y-5.5%-5.7%+0.2%

1.2. Operating Efficiency of Kuros Biosciences AG.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Kuros is operating .

  • Measures how much profit Kuros makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Kuros to the Medical Devices industry mean.
  • An Operating Margin of -20.5% means the company generated $-0.21  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Kuros Biosciences AG:

  • The MRQ is -20.5%. The company is operating very inefficient. -2
  • The TTM is -28.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-20.5%TTM-28.0%+7.4%
TTM-28.0%YOY-56.2%+28.2%
TTM-28.0%5Y-75.7%+47.7%
5Y-75.7%10Y-8,491.3%+8,415.6%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-20.5%-28.6%+8.1%
TTM-28.0%-13.8%-14.2%
YOY-56.2%-14.5%-41.7%
5Y-75.7%-18.9%-56.8%
10Y-8,491.3%-24.4%-8,466.9%
1.2.2. Operating Ratio

Measures how efficient Kuros is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Devices industry mean).
  • An Operation Ratio of 1.21 means that the operating costs are $1.21 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Kuros Biosciences AG:

  • The MRQ is 1.205. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.339. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.205TTM1.339-0.134
TTM1.339YOY1.444-0.105
TTM1.3395Y1.261+0.078
5Y1.26110Y116.350-115.089
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2051.424-0.219
TTM1.3391.431-0.092
YOY1.4441.396+0.048
5Y1.2611.413-0.152
10Y116.3501.375+114.975

1.3. Liquidity of Kuros Biosciences AG.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Kuros is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Devices industry mean).
  • A Current Ratio of 2.06 means the company has $2.06 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Kuros Biosciences AG:

  • The MRQ is 2.062. The company is able to pay all its short-term debts. +1
  • The TTM is 2.159. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.062TTM2.159-0.097
TTM2.159YOY2.462-0.303
TTM2.1595Y4.611-2.452
5Y4.61110Y4.497+0.114
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0622.689-0.627
TTM2.1592.724-0.565
YOY2.4623.418-0.956
5Y4.6113.658+0.953
10Y4.4973.632+0.865
1.3.2. Quick Ratio

Measures if Kuros is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Kuros to the Medical Devices industry mean.
  • A Quick Ratio of 1.66 means the company can pay off $1.66 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Kuros Biosciences AG:

  • The MRQ is 1.655. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.701. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.655TTM1.701-0.046
TTM1.701YOY1.784-0.083
TTM1.7015Y2.511-0.810
5Y2.51110Y2.378+0.133
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6551.494+0.161
TTM1.7011.532+0.169
YOY1.7842.100-0.316
5Y2.5112.336+0.175
10Y2.3782.596-0.218

1.4. Solvency of Kuros Biosciences AG.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Kuros assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Kuros to Medical Devices industry mean.
  • A Debt to Asset Ratio of 0.25 means that Kuros assets are financed with 25.3% credit (debt) and the remaining percentage (100% - 25.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Kuros Biosciences AG:

  • The MRQ is 0.253. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.206. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.253TTM0.206+0.047
TTM0.206YOY0.167+0.039
TTM0.2065Y0.143+0.064
5Y0.14310Y0.139+0.004
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2530.417-0.164
TTM0.2060.401-0.195
YOY0.1670.335-0.168
5Y0.1430.441-0.298
10Y0.1390.454-0.315
1.4.2. Debt to Equity Ratio

Measures if Kuros is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Kuros to the Medical Devices industry mean.
  • A Debt to Equity ratio of 33.8% means that company has $0.34 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Kuros Biosciences AG:

  • The MRQ is 0.338. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.261. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.338TTM0.261+0.077
TTM0.261YOY0.200+0.061
TTM0.2615Y0.169+0.092
5Y0.16910Y0.164+0.006
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3380.601-0.263
TTM0.2610.607-0.346
YOY0.2000.487-0.287
5Y0.1690.640-0.471
10Y0.1640.682-0.518

2. Market Valuation of Kuros Biosciences AG

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Kuros generates.

  • Above 15 is considered overpriced but always compare Kuros to the Medical Devices industry mean.
  • A PE ratio of -3.74 means the investor is paying $-3.74 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Kuros Biosciences AG:

  • The EOD is -8.744. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.741. Based on the earnings, the company is expensive. -2
  • The TTM is -4.340. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.744MRQ-3.741-5.003
MRQ-3.741TTM-4.340+0.599
TTM-4.340YOY-6.575+2.235
TTM-4.3405Y-47.488+43.147
5Y-47.48810Y-31.658-15.829
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD-8.744-1.143-7.601
MRQ-3.741-1.704-2.037
TTM-4.340-2.344-1.996
YOY-6.575-2.982-3.593
5Y-47.488-2.449-45.039
10Y-31.658-2.057-29.601
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Kuros Biosciences AG:

  • The EOD is -32.500. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -13.905. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -9.092. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-32.500MRQ-13.905-18.595
MRQ-13.905TTM-9.092-4.813
TTM-9.092YOY-14.882+5.790
TTM-9.0925Y-4.795-4.297
5Y-4.79510Y-3.197-1.598
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD-32.500-1.960-30.540
MRQ-13.905-3.111-10.794
TTM-9.092-3.078-6.014
YOY-14.882-5.861-9.021
5Y-4.795-5.350+0.555
10Y-3.197-5.716+2.519
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Kuros is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Devices industry mean).
  • A PB ratio of 2.50 means the investor is paying $2.50 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Kuros Biosciences AG:

  • The EOD is 5.853. Based on the equity, the company is overpriced. -1
  • The MRQ is 2.504. Based on the equity, the company is underpriced. +1
  • The TTM is 1.519. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD5.853MRQ2.504+3.349
MRQ2.504TTM1.519+0.985
TTM1.519YOY1.061+0.458
TTM1.5195Y1.059+0.460
5Y1.05910Y0.706+0.353
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD5.8532.067+3.786
MRQ2.5042.362+0.142
TTM1.5192.532-1.013
YOY1.0612.943-1.882
5Y1.0594.061-3.002
10Y0.7064.533-3.827
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Kuros Biosciences AG compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.008-0.082+1095%-0.055+765%-0.027+424%0.047-83%
Book Value Per Share--1.5381.634-6%1.952-21%1.977-22%1.909-19%
Current Ratio--2.0622.159-4%2.462-16%4.611-55%4.497-54%
Debt To Asset Ratio--0.2530.206+23%0.167+52%0.143+77%0.139+82%
Debt To Equity Ratio--0.3380.261+29%0.200+69%0.169+100%0.164+107%
Dividend Per Share----0%-0%-0%-0%
Eps---0.257-0.153-41%-0.108-58%-0.097-62%-0.097-62%
Free Cash Flow Per Share---0.069-0.102+47%-0.081+17%-0.093+34%-0.093+34%
Free Cash Flow To Equity Per Share---0.065-0.104+59%-0.032-51%-0.073+12%-0.073+12%
Gross Profit Margin--1.8072.298-21%1.437+26%1.247+45%1.165+55%
Intrinsic Value_10Y_max---4.396--------
Intrinsic Value_10Y_min---3.784--------
Intrinsic Value_1Y_max---0.382--------
Intrinsic Value_1Y_min---0.375--------
Intrinsic Value_3Y_max---1.192--------
Intrinsic Value_3Y_min---1.137--------
Intrinsic Value_5Y_max---2.056--------
Intrinsic Value_5Y_min---1.905--------
Market Cap331909200.000+57%142001819.40090095124.120+58%76615707.000+85%75734346.824+87%50489564.549+181%
Net Profit Margin---0.419-0.406-3%-0.809+93%-0.817+95%-75.766+17977%
Operating Margin---0.205-0.280+36%-0.562+174%-0.757+269%-84.913+41283%
Operating Ratio--1.2051.339-10%1.444-17%1.261-4%116.350-99%
Pb Ratio5.853+57%2.5041.519+65%1.061+136%1.059+136%0.706+255%
Pe Ratio-8.744-134%-3.741-4.340+16%-6.575+76%-47.488+1169%-31.658+746%
Price Per Share9.000+57%3.8512.440+58%2.078+85%2.053+88%1.369+181%
Price To Free Cash Flow Ratio-32.500-134%-13.905-9.092-35%-14.882+7%-4.795-66%-3.197-77%
Price To Total Gains Ratio1087.644+57%465.33017535.410-97%-17.535+104%6394.084-93%6394.084-93%
Quick Ratio--1.6551.701-3%1.784-7%2.511-34%2.378-30%
Return On Assets---0.125-0.074-41%-0.071-43%-0.044-64%-0.047-63%
Return On Equity---0.167-0.095-43%-0.085-49%-0.053-68%-0.055-67%
Total Gains Per Share--0.008-0.082+1095%-0.055+765%-0.027+424%0.047-83%
Usd Book Value--56712000.00060336250.000-6%71974750.000-21%72939550.000-22%70423496.722-19%
Usd Book Value Change Per Share--0.008-0.082+1095%-0.055+765%-0.027+424%0.047-83%
Usd Book Value Per Share--1.5381.634-6%1.952-21%1.977-22%1.909-19%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.257-0.153-41%-0.108-58%-0.097-62%-0.097-62%
Usd Free Cash Flow---2553162.600-3760417.988+47%-2234700.963-12%-1199023.790-53%-799349.193-69%
Usd Free Cash Flow Per Share---0.069-0.102+47%-0.081+17%-0.093+34%-0.093+34%
Usd Free Cash Flow To Equity Per Share---0.065-0.104+59%-0.032-51%-0.073+12%-0.073+12%
Usd Market Cap331909200.000+57%142001819.40090095124.120+58%76615707.000+85%75734346.824+87%50489564.549+181%
Usd Price Per Share9.000+57%3.8512.440+58%2.078+85%2.053+88%1.369+181%
Usd Profit---9489582.500-5630986.988-41%-5987051.438-37%-3652039.845-62%-3628751.112-62%
Usd Revenue--22641542.20013768372.350+64%5952456.850+280%3993938.290+467%2708387.010+736%
Usd Total Gains Per Share--0.008-0.082+1095%-0.055+765%-0.027+424%0.047-83%
 EOD+6 -2MRQTTM+16 -18YOY+15 -195Y+17 -1710Y+13 -21

3.2. Fundamental Score

Let's check the fundamental score of Kuros Biosciences AG based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-8.744
Price to Book Ratio (EOD)Between0-15.853
Net Profit Margin (MRQ)Greater than0-0.419
Operating Margin (MRQ)Greater than0-0.205
Quick Ratio (MRQ)Greater than11.655
Current Ratio (MRQ)Greater than12.062
Debt to Asset Ratio (MRQ)Less than10.253
Debt to Equity Ratio (MRQ)Less than10.338
Return on Equity (MRQ)Greater than0.15-0.167
Return on Assets (MRQ)Greater than0.05-0.125
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Kuros Biosciences AG based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5064.911
Ma 20Greater thanMa 508.100
Ma 50Greater thanMa 1007.574
Ma 100Greater thanMa 2006.679
OpenGreater thanClose9.000
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets75,906
Total Liabilities19,194
Total Stockholder Equity56,712
 As reported
Total Liabilities 19,194
Total Stockholder Equity+ 56,712
Total Assets = 75,906

Assets

Total Assets75,906
Total Current Assets27,194
Long-term Assets48,712
Total Current Assets
Cash And Cash Equivalents 14,208
Net Receivables 7,617
Inventory 4,856
Other Current Assets 513
Total Current Assets  (as reported)27,194
Total Current Assets  (calculated)27,194
+/-0
Long-term Assets
Property Plant Equipment 2,642
Goodwill 24,469
Intangible Assets 16,508
Long-term Assets  (as reported)48,712
Long-term Assets  (calculated)43,619
+/- 5,093

Liabilities & Shareholders' Equity

Total Current Liabilities13,187
Long-term Liabilities6,007
Total Stockholder Equity56,712
Total Current Liabilities
Short-term Debt 3,953
Accounts payable 1,301
Other Current Liabilities 7,933
Total Current Liabilities  (as reported)13,187
Total Current Liabilities  (calculated)13,187
+/-0
Long-term Liabilities
Capital Lease Obligations 2,143
Long-term Liabilities  (as reported)6,007
Long-term Liabilities  (calculated)2,143
+/- 3,864
Total Stockholder Equity
Common Stock3,678
Retained Earnings -42,151
Accumulated Other Comprehensive Income 21,886
Other Stockholders Equity 73,299
Total Stockholder Equity (as reported)56,712
Total Stockholder Equity (calculated)56,712
+/-0
Other
Capital Stock3,678
Cash and Short Term Investments 14,208
Common Stock Shares Outstanding 36,604
Liabilities and Stockholders Equity 75,906
Net Debt -8,690
Net Invested Capital 56,712
Net Working Capital 14,007
Property Plant and Equipment Gross 3,713
Short Long Term Debt Total 5,518



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302015-12-312015-06-302014-12-312014-06-302013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-31
> Total Assets 
0
0
0
68,702
56,480
64,130
59,617
54,071
48,547
43,130
38,774
30,813
9,292
37,854
35,797
30,391
25,322
19,683
16,770
40,502
19,395
17,631
2,886
3,259
48,665
43,768
43,768
90,895
90,895
68,815
86,081
78,967
78,967
85,821
85,821
81,128
81,128
0
87,852
0
80,825
0
94,364
0
93,491
0
91,336
0
88,269
82,946
82,946
78,256
78,256
71,464
75,906
75,90671,46478,25678,25682,94682,94688,269091,336093,491094,364080,825087,852081,12881,12885,82185,82178,96778,96786,08168,81590,89590,89543,76843,76848,6653,2592,88617,63119,39540,50216,77019,68325,32230,39135,79737,8549,29230,81338,77443,13048,54754,07159,61764,13056,48068,702000
   > Total Current Assets 
0
0
0
62,661
50,978
59,138
55,117
50,048
44,855
39,923
35,658
30,570
9,068
37,568
35,494
30,237
25,176
19,525
16,614
40,337
19,323
17,551
2,806
3,179
17,940
13,396
13,396
23,722
23,722
14,129
17,674
10,855
10,855
19,833
19,833
14,432
14,432
23,290
23,290
17,747
17,747
33,968
33,968
31,515
31,515
32,892
32,892
32,245
32,245
31,393
31,393
27,087
27,087
27,194
27,194
27,19427,19427,08727,08731,39331,39332,24532,24532,89232,89231,51531,51533,96833,96817,74717,74723,29023,29014,43214,43219,83319,83310,85510,85517,67414,12923,72223,72213,39613,39617,9403,1792,80617,55119,32340,33716,61419,52525,17630,23735,49437,5689,06830,57035,65839,92344,85550,04855,11759,13850,97862,661000
       Cash And Cash Equivalents 
0
0
0
20,969
10,916
21,944
18,464
33,782
33,393
29,081
29,606
24,542
7,141
35,851
33,891
28,585
23,427
17,813
13,888
39,847
18,382
16,935
2,163
2,093
17,446
12,369
12,369
21,417
21,417
13,329
16,673
9,650
9,650
18,334
18,334
12,615
12,615
0
20,802
0
15,212
0
28,388
0
27,221
0
28,623
0
21,557
24,065
24,065
16,861
16,861
14,208
14,208
14,20814,20816,86116,86124,06524,06521,557028,623027,221028,388015,212020,802012,61512,61518,33418,3349,6509,65016,67313,32921,41721,41712,36912,36917,4462,0932,16316,93518,38239,84713,88817,81323,42728,58533,89135,8517,14124,54229,60629,08133,39333,78218,46421,94410,91620,969000
       Short-term Investments 
0
0
0
37,000
37,000
28,000
28,000
8,000
8,000
8,000
4,000
4,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000004,0004,0008,0008,0008,00028,00028,00037,00037,000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
681
681
854
854
311
351
456
456
627
627
821
821
1,075
1,075
831
831
1,402
3,573
2,179
2,179
2,047
2,047
7,812
7,812
2,817
3,618
4,162
5,180
6,411
7,617
7,6176,4115,1804,1623,6182,8177,8127,8122,0472,0472,1792,1793,5731,4028318311,0751,0758218216276274564563513118548546816810000000000000000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,593
1,469
1,583
336
629
496
338
0
0
0
35
0
0
103
430
0
332
0
325
0
331
0
459
0
474
2,171
547
0
736
0
465
0
534
1,341
540
1,675
657
1,719
513
5131,7196571,6755401,3415340465073605472,1714740459033103250332043010300350003384966293361,5831,4691,5930000000000000000
   > Long-term Assets 
0
0
0
6,041
5,502
4,992
4,500
4,023
3,692
3,207
3,116
243
224
286
303
154
146
158
156
165
72
80
80
80
30,725
0
30,372
0
67,173
0
68,407
0
68,112
0
65,988
0
66,696
0
64,562
0
63,078
0
60,396
0
61,976
0
58,444
0
56,024
51,553
51,553
51,169
51,168
44,270
48,712
48,71244,27051,16851,16951,55351,55356,024058,444061,976060,396063,078064,562066,696065,988068,112068,407067,173030,372030,725808080721651561581461543032862242433,1163,2073,6924,0234,5004,9925,5026,041000
       Property Plant Equipment 
0
0
0
5,993
5,454
4,944
4,452
3,968
3,637
3,152
2,680
137
118
104
101
86
79
91
89
93
0
0
0
0
48
45
45
325
325
504
630
648
648
634
634
3,043
3,043
2,782
2,782
2,758
2,758
2,588
2,588
2,719
2,719
2,447
2,447
2,175
2,176
2,323
2,323
3,213
3,213
2,642
2,642
2,6422,6423,2133,2132,3232,3232,1762,1752,4472,4472,7192,7192,5882,5882,7582,7582,7822,7823,0433,043634634648648630504325325454548000093899179861011041181372,6803,1523,6373,9684,4524,9445,4545,993000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23,717
23,717
23,717
33,825
33,825
27,617
34,546
34,503
34,503
34,241
34,241
34,083
34,083
0
33,860
0
33,716
0
33,847
0
33,964
0
33,390
0
33,037
29,314
29,314
29,245
29,245
24,469
24,469
24,46924,46929,24529,24529,31429,31433,037033,390033,964033,847033,716033,860034,08334,08334,24134,24134,50334,50334,54627,61733,82533,82523,71723,71723,717000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,945
6,595
6,595
33,023
33,023
26,566
33,231
32,961
32,962
31,113
31,113
29,570
29,570
0
27,920
0
26,604
0
23,666
0
24,985
0
22,607
0
20,758
19,412
19,412
18,214
18,214
16,508
16,508
16,50816,50818,21418,21419,41219,41220,758022,607024,985023,666026,604027,920029,57029,57031,11331,11332,96232,96133,23126,56633,02333,0236,5956,5956,945000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15
15
0
0
0
0
0
0
0
0
0
0
0
0
0
0
295
295
308
308
0
0
54
54
504
504
497
1
0
0
0014975045045454003083082952950000000000000015150000000000000000000000000
> Total Liabilities 
0
0
0
60,461
52,409
45,394
46,628
47,476
47,142
46,315
47,822
42,493
16,516
18,550
21,969
20,362
20,801
22,846
27,133
36,272
37,559
43,851
1,563
2,590
5,717
5,446
5,446
13,247
13,247
10,345
12,941
10,268
10,268
9,338
9,338
9,945
9,945
0
9,997
0
8,725
0
9,763
0
8,536
0
14,360
0
15,066
14,086
14,086
14,296
14,295
14,752
19,194
19,19414,75214,29514,29614,08614,08615,066014,36008,53609,76308,72509,99709,9459,9459,3389,33810,26810,26812,94110,34513,24713,2475,4465,4465,7172,5901,56343,85137,55936,27227,13322,84620,80120,36221,96918,55016,51642,49347,82246,31547,14247,47646,62845,39452,40960,461000
   > Total Current Liabilities 
0
0
0
4,859
3,952
3,475
4,295
4,469
3,659
2,358
6,369
39,560
2,733
1,486
4,069
3,490
2,420
2,577
4,952
5,810
36,959
43,851
1,562
1,696
2,304
3,265
3,265
4,870
4,870
3,722
4,656
2,959
2,959
4,040
4,040
3,117
3,117
3,640
3,640
3,095
3,095
3,876
3,876
3,740
3,740
11,288
11,288
13,271
13,271
12,589
12,589
12,007
12,007
13,187
13,187
13,18713,18712,00712,00712,58912,58913,27113,27111,28811,2883,7403,7403,8763,8763,0953,0953,6403,6403,1173,1174,0404,0402,9592,9594,6563,7224,8704,8703,2653,2652,3041,6961,56243,85136,9595,8104,9522,5772,4203,4904,0691,4862,73339,5606,3692,3583,6594,4694,2953,4753,9524,859000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
35,715
0
0
0
0
0
0
0
0
31,329
37,592
0
0
0
0
0
0
0
0
0
0
0
0
0
0
660
0
246
0
376
0
278
0
310
0
317
0
308
0
416
0
578
0
3,953
3,9530578041603080317031002780376024606600000000000000037,59231,3290000000035,71500000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
412
0
0
0
104
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000104000412000000000000000000000000000000000000
       Accounts payable 
0
0
0
253
546
994
714
541
895
554
512
328
436
269
654
362
457
368
927
1,492
58
152
107
315
1,176
1,273
1,273
1,582
1,582
1,055
1,320
911
911
1,611
1,611
673
673
1,059
1,059
490
490
936
936
601
601
846
846
920
920
1,302
1,302
1,186
1,186
1,301
1,301
1,3011,3011,1861,1861,3021,3029209208468466016019369364904901,0591,0596736731,6111,6119119111,3201,0551,5821,5821,2731,2731,176315107152581,492927368457362654269436328512554895541714994546253000
       Other Current Liabilities 
0
0
0
4,606
3,406
2,481
3,581
3,928
2,764
1,804
5,857
3,517
2,297
1,217
3,415
3,128
1,963
2,209
4,025
4,318
5,572
6,107
1,455
1,381
1,128
0
1,992
0
3,288
165
3,336
75
2,048
0
2,429
0
1,784
0
2,335
0
2,229
0
2,662
166
2,829
6,463
10,125
8,426
12,043
11,287
10,871
10,821
10,243
11,886
7,933
7,93311,88610,24310,82110,87111,28712,0438,42610,1256,4632,8291662,66202,22902,33501,78402,42902,048753,3361653,28801,99201,1281,3811,4556,1075,5724,3184,0252,2091,9633,1283,4151,2172,2973,5175,8571,8042,7643,9283,5812,4813,4064,606000
   > Long-term Liabilities 
0
0
0
55,602
48,457
41,919
42,333
43,007
43,483
43,957
41,453
2,933
13,783
17,064
17,900
16,872
18,381
20,269
22,181
30,462
600
0
1
894
3,413
0
2,181
0
8,377
0
8,285
0
7,309
0
5,298
0
6,828
0
6,357
0
5,630
0
5,887
0
4,796
0
3,072
0
1,795
1,497
1,497
2,289
2,288
1,565
6,007
6,0071,5652,2882,2891,4971,4971,79503,07204,79605,88705,63006,35706,82805,29807,30908,28508,37702,18103,4138941060030,46222,18120,26918,38116,87217,90017,06413,7832,93341,45343,95743,48343,00742,33341,91948,45755,602000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,181
2,181
8,377
8,377
6,623
6,604
7,309
7,309
5,298
5,298
4,515
4,515
4,215
4,215
3,457
3,457
3,825
3,825
2,702
2,702
1,243
1,243
163
163
0
0
0
0
0
0
0000001631631,2431,2432,7022,7023,8253,8253,4573,4574,2154,2154,5154,5155,2985,2987,3097,3096,6046,6238,3778,3772,1812,1810000000000000000000000000
> Total Stockholder Equity
0
0
0
8,241
4,071
18,736
12,989
6,595
1,405
-3,185
-9,048
-11,680
-7,224
19,304
13,828
10,029
4,521
-3,163
-10,363
4,230
-18,164
-26,220
1,323
669
42,948
38,322
38,322
77,648
77,648
58,470
73,140
68,699
68,699
76,483
76,483
71,183
71,183
0
77,855
0
72,100
0
84,601
0
84,955
0
76,976
0
73,203
68,860
68,860
63,960
63,961
56,712
56,712
56,71256,71263,96163,96068,86068,86073,203076,976084,955084,601072,100077,855071,18371,18376,48376,48368,69968,69973,14058,47077,64877,64838,32238,32242,9486691,323-26,220-18,1644,230-10,363-3,1634,52110,02913,82819,304-7,224-11,680-9,048-3,1851,4056,59512,98918,7364,0718,241000
   Common Stock
0
0
0
527
527
527
527
527
527
527
527
527
576
2,241
2,241
2,241
2,241
2,241
2,241
3,053
3,053
3,053
3,240
3,240
5,084
5,084
5,084
7,601
7,601
6,532
8,171
8,233
8,233
15,059
15,059
15,204
15,204
22,470
22,470
22,470
22,470
32,811
32,811
32,811
32,811
3,281
3,281
3,281
3,281
3,656
3,656
3,656
3,656
3,678
3,678
3,6783,6783,6563,6563,6563,6563,2813,2813,2813,28132,81132,81132,81132,81122,47022,47022,47022,47015,20415,20415,05915,0598,2338,2338,1716,5327,6017,6015,0845,0845,0843,2403,2403,0533,0533,0532,2412,2412,2412,2412,2412,241576527527527527527527527527527000
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
20,214
20,898
20,898
21,036
21,036
21,886
21,886
21,88621,88621,03621,03620,89820,89820,214000000000000000000000000000000000000000000000000
   Capital Surplus 0000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
217,793
217,437
217,099
217,362
217,611
217,735
217,871
218,102
218,119
219,953
247,430
247,170
247,330
247,529
247,990
248,366
272,044
273,119
275,982
295,635
297,419
75,219
15,934
76,576
17,359
119,853
14,368
122,126
18,381
122,697
18,648
130,857
18,929
131,303
19,146
137,289
19,541
137,684
19,898
144,942
20,134
145,178
20,709
174,861
20,214
154,727
160,140
160,559
160,140
160,538
73,299
73,299
73,29973,299160,538160,140160,559160,140154,72720,214174,86120,709145,17820,134144,94219,898137,68419,541137,28919,146131,30318,929130,85718,648122,69718,381122,12614,368119,85317,35976,57615,93475,219297,419295,635275,982273,119272,044248,366247,990247,529247,330247,170247,430219,953218,119218,102217,871217,735217,611217,362217,099217,437217,793000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in CHF. All numbers in thousands.